For decades, Group B Streptococcus has presented doctors with a deceptively simple question: why do some newborns develop a rapidly progressing infection within hours of birth, while others become ill days or weeks later? A study by M. Murra, T.B. Henriksen, M. Andersen and colleagues, published in Nature Communications in 2026, suggests that the answer cannot be found by examining the bacterium alone. The timing of disease appears to depend on an interaction between the organism’s genetic characteristics and the gestational age at which a baby is born, adding a new layer of biological complexity to one of the most serious bacterial threats facing newborns.
Group B Streptococcus, commonly abbreviated GBS or Streptococcus agalactiae, is a bacterium that can colonize the gastrointestinal and genital tracts without causing symptoms in adults. During pregnancy, however, a colonized mother can transmit the organism to her infant before, during or shortly after delivery. Most exposed babies remain healthy, but some develop invasive disease, in which bacteria enter normally sterile sites such as the bloodstream, lungs or central nervous system. In newborns, the consequences can be severe, including sepsis, pneumonia and meningitis. Clinicians generally divide GBS disease into early-onset disease, occurring during the first days of life, and late-onset disease, emerging later in infancy.
That classification is clinically useful, but it can also conceal important biological variation. A baby born prematurely does not enter the world with the same immune maturity, lung development, skin barrier function or microbial environment as a full-term infant. Prematurity may also change the duration and route of exposure to GBS, including whether transmission occurs before birth, during labor or after delivery. The new research focuses on this interaction, asking whether the association between a GBS strain’s genome and the age at which disease appears changes according to gestational age—the number of weeks of pregnancy completed before birth.
The investigators’ approach reflects a broader transformation in infectious-disease research. Instead of treating GBS as a single, uniform pathogen, genomic epidemiology views it as a population of related but genetically diverse bacterial lineages. Whole-genome sequencing can identify differences across bacterial strains, including their capsular types, sequence lineages and genes associated with colonization, immune evasion, toxin production, surface attachment or antimicrobial resistance. These features do not operate in isolation, and the presence of a gene does not automatically prove that it causes more severe disease. Nevertheless, genome-wide data can reveal patterns that are invisible when infections are classified only by symptoms or by the broad label of “GBS.”
The central finding signaled by the study is that gestational age modifies the relationship between genomic characteristics and postnatal age at disease onset. In statistical terms, gestational age functions as an effect modifier: the strength or direction of an association between bacterial genetic features and disease timing is not necessarily the same for preterm and full-term infants. This distinction is important. An effect modifier is not simply another risk factor added to a list; it changes how researchers must interpret the relationship between two variables. A strain characteristic associated with earlier disease in one gestational-age group may show a weaker association, or a different pattern, in another.
This finding offers a possible explanation for why efforts to identify universally “high-risk” GBS strains have often produced an incomplete picture. A bacterial lineage may be particularly successful at causing disease shortly after birth in infants whose immune systems and physiological barriers are still immature, while the same lineage may behave differently in more mature newborns. Conversely, genetic traits that matter during later infant disease could have less influence during the earliest hours of life, when exposure route, delivery circumstances and maternal-to-infant transmission may dominate. The bacterium’s genome remains important, but its effects are filtered through the developmental state of the host.
The study also highlights why gestational age must be integrated into genomic surveillance and clinical research rather than treated as a background demographic detail. Premature infants are already known to face elevated risks of infection because their immune responses are developing and because they often require invasive medical support. If particular GBS genomic profiles are linked to distinct onset patterns within specific gestational-age groups, future surveillance systems may be able to detect more precise warning signals. Such systems could combine maternal colonization data, neonatal symptoms, delivery history and bacterial sequencing to estimate which infants require especially close observation after birth.
The implications extend to prevention, although the research does not by itself create a new diagnostic test or treatment. Current prevention strategies include screening pregnant women for GBS colonization and administering antibiotics during labor when indicated. These measures have helped reduce many cases of early-onset disease, but they do not eliminate all infections, and they offer limited protection against disease that develops later. A clearer understanding of how bacterial genomes interact with fetal maturity could inform the design of vaccines, refine risk models and help researchers determine whether prevention should be tailored to particular bacterial lineages or clinical settings. It could also encourage more careful interpretation of studies that combine preterm and term infants into a single analysis.
For families and clinicians, the work reinforces a practical message: the timing of symptoms is biologically meaningful, but it should never be used to dismiss a newborn’s sudden deterioration. GBS sepsis can progress quickly, and signs such as poor feeding, breathing difficulty, unusual sleepiness, temperature instability or changes in muscle tone require urgent medical assessment. The study does not suggest that parents can identify dangerous strains themselves, nor does it imply that genomic information can replace clinical care. Instead, it shows why the same bacterial species can produce different disease trajectories in different newborns, and why a more personalized understanding of neonatal infection is becoming possible.
The broader lesson is that infectious disease is shaped by a three-way conversation between pathogen, host and time. GBS carries a genome that influences how it survives and spreads, but the newborn provides a changing biological environment, one that differs dramatically between a very premature infant and a baby born at term. By demonstrating that gestational age modifies associations between bacterial genomic characteristics and the postnatal timing of disease, Murra, Henriksen, Andersen and colleagues move the field beyond one-size-fits-all descriptions of neonatal GBS infection. Their work points toward a future in which genomic epidemiology is combined with developmental biology to explain not only who becomes infected, but also why disease emerges when it does.
Subject of Research: The interaction between Group B Streptococcus genomic characteristics, gestational age and the timing of neonatal disease onset.
Article Title: Gestational age modifies associations between Group B Streptococcus genomic characteristics and postnatal age at disease onset.
Article References: Murra, M., Henriksen, T.B., Andersen, M. et al. “Gestational age modifies associations between Group B Streptococcus genomic characteristics and postnatal age at disease onset.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76999-y
Image Credits: AI Generated
DOI: 10.1038/s41467-026-76999-y
Keywords: Group B Streptococcus, neonatal sepsis, genomic epidemiology, gestational age, preterm infants, early-onset disease, late-onset disease, neonatal infection, whole-genome sequencing, bacterial genomics
